Metabolic & weight · Peptide medicine

Pramlintide

Also known as pramlintide acetate, Symlin, SymlinPen

A synthetic analogue of amylin used in the FDA-approved SymlinPen product as an adjunct to mealtime insulin in defined diabetes contexts.[1]

Compare

Prepare questions

Published evidenceHuman evidence

Human studies are available in defined contexts, but the evidence remains product-, population-, route-, or outcome-specific.

U.S. status: FDA-approved product for specific uses
Published context: GLP-1, metabolic and weight-management
Form and route: SymlinPen injection · Subcutaneous
Main uncertainty: Safe use depends heavily on the labeled insulin context and patient selection. The evidence does not support use as a stand-alone weight-management product or outside clinician-directed diabetes care.

Reviewed Jul 22, 2026 · U.S.-focused reference profile

Read the context, not only the compound name. Evidence and status can change with the form, route, population, and use. This profile does not assess individual suitability.

Orientation

What this is

Start with identity and research context. Similar names do not establish equivalent products or evidence.

Published name: Pramlintide
Type: Peptide medicine
Primary topic: Metabolic and weight-related medicines and research
Aliases: pramlintide acetate, Symlin, SymlinPen

Where it has been studied or used

Published research or product contexts. These are not personal indications.

GLP-1, metabolic and weight-management

Why exact identity matters

Evidence can change with chemical form, formulation, route, ingredients, and manufacturing. A brand, salt, fragment, or cosmetic ingredient may not represent the same evidence.

What is known

Evidence, in context

Overall published evidenceHuman evidence in specific contexts

Human studies are available in defined contexts, but the evidence remains product-, population-, route-, or outcome-specific. This is a description, not a rating or recommendation.

GLP-1, metabolic and weight-management

Published human evidence context

Human evidence

Controlled clinical studies in FDA labeling support pramlintide as an adjunct to mealtime insulin in selected adults with type 1 or type 2 diabetes who have not achieved desired glucose control despite appropriate insulin management.

Form: SymlinPen injection
Route: Subcutaneous

Limits and source

Safe use depends heavily on the labeled insulin context and patient selection. The evidence does not support use as a stand-alone weight-management product or outside clinician-directed diabetes care.

Pramlintide

What this is

Where it has been studied or used

Evidence, in context

Published human evidence context

Risks and unknowns

Published risk information

What remains uncertain

Forms and routes

SymlinPen injection

U.S. status

FDA-approved medicine

Questions worth discussing

Already following a plan involving Pramlintide?

Sources and methodology